Argenx posts Q3 2026 sales surge and announces Forte Biosciences acquisition
Argenx reported third‑quarter 2026 product net sales of about $1.7 billion, up roughly 54 % year‑over‑year, driven by VYVGART. Net income rose to $506 million and earnings per share reached $7.80. The company completed a $2.2 billion acquisition of Forte Biosciences and said it expects combined R&D and SG&A expenses of about $4 billion in 2026. It also announced that Phase 3 data for empasiprubart are slated for December 2026 and that FB102 will move into a Phase 3 trial in celiac disease.
Why it matters
The revenue jump and acquisition expand Argenx’s product portfolio, but higher R&D and integration costs compress operating margin, which investors must weigh. Future Phase 3 readouts could drive further upside if the trials are positive, as the company highlighted in its update.
Key facts
- 1Product net sales were $1.7 billion in Q3 2026, a 54 % year‑over‑year increase. stocktitan.net
- 2Net income for the quarter was $506 million. rttnews.com
- 3Earnings per share were $7.80, up from $5.18 a year earlier. rttnews.com
- 4Argenx completed a $2.2 billion acquisition of Forte Biosciences. globalbankingandfinance.com
- 5The company expects combined R&D and SG&A expenses of approximately $4 billion in 2026. seekingalpha.com
- 6Phase 3 data for empasiprubart are expected in December 2026. marketscreener.com
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.